| Access Wellness Healthcare Corp | |
|
165 Sw Vision Gln Lake City FL 32025-1111 | |
| (386) 755-1800 | |
| Not Available |
| Full Name | Access Wellness Healthcare Corp |
|---|---|
| Speciality | Psychiatry & Neurology |
| Location | 165 Sw Vision Gln, Lake City, Florida |
| Authorized Official Name and Position | Umesh Mhatre (CHAIRMAN) |
| Authorized Official Contact | 3867551800 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Access Wellness Healthcare Corp 5915 Sw 49th Ave Ocala FL 34474-5701 Ph: () - | Access Wellness Healthcare Corp 165 Sw Vision Gln Lake City FL 32025-1111 Ph: (386) 755-1800 |
| NPI Number | 1326757204 |
|---|---|
| Provider Enumeration Date | 11/18/2022 |
| Last Update Date | 03/03/2023 |
| Certification Date | 03/03/2023 |
| Medicare PECOS PAC ID | 0143693218 |
|---|---|
| Medicare Enrollment ID | O20230310001772 |
News Archive
Connected health infrastructure is emerging as a binding agent for diverse devices and workflows, aiding diagnosis, monitoring and prevention in the healthcare industry. For such an infrastructure to be efficient, stakeholders must first ensure that interoperability and connectivity standards are in place.
RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that the first participant in its Phase 1/2 clinical trial of RCT-01, being tested for the treatment of chronic unilateral Achilles tendinosis, has been enrolled and their tissue biopsy sent for processing prior to intra-tendon ultrasound-guided injections.
Jiangbo Pharmaceuticals, Inc., a pharmaceutical company with its principal operations in the People's Republic of China, today announced that it has reached a settlement with the holder of its November 2007 Debenture and with the holders of its May 2008 Notes under which the Company has agreed to issue to such holders a total of 886,277 shares of its common stock as a payment for all delinquent interest and associated penalties with respect to its November 2007 Debenture and May 2008 Notes.
Amid the coronavirus disease (COVID-19) outbreak, scientists from around the globe race to fight the deadly virus. Now, a team of Harvard scientists has joined forces with Chinese experts to develop new therapies and prevent the further spread of the virus.
Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Tolterodine Tartrate Extended-release Capsules, 2 mg and 4 mg. Tolterodine Tartrate ER Capsules are the generic version of Pfizer's Detrol LA, and are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326757204 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | (* (Not Available)) | Primary |
| 208D00000X | General Practice | (* (Not Available)) | Secondary |
| Provider Name | Parikshit Deshmukh |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1437395845 PECOS PAC ID: 3173789948 Enrollment ID: I20120723000717 |
News Archive
Connected health infrastructure is emerging as a binding agent for diverse devices and workflows, aiding diagnosis, monitoring and prevention in the healthcare industry. For such an infrastructure to be efficient, stakeholders must first ensure that interoperability and connectivity standards are in place.
RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that the first participant in its Phase 1/2 clinical trial of RCT-01, being tested for the treatment of chronic unilateral Achilles tendinosis, has been enrolled and their tissue biopsy sent for processing prior to intra-tendon ultrasound-guided injections.
Jiangbo Pharmaceuticals, Inc., a pharmaceutical company with its principal operations in the People's Republic of China, today announced that it has reached a settlement with the holder of its November 2007 Debenture and with the holders of its May 2008 Notes under which the Company has agreed to issue to such holders a total of 886,277 shares of its common stock as a payment for all delinquent interest and associated penalties with respect to its November 2007 Debenture and May 2008 Notes.
Amid the coronavirus disease (COVID-19) outbreak, scientists from around the globe race to fight the deadly virus. Now, a team of Harvard scientists has joined forces with Chinese experts to develop new therapies and prevent the further spread of the virus.
Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Tolterodine Tartrate Extended-release Capsules, 2 mg and 4 mg. Tolterodine Tartrate ER Capsules are the generic version of Pfizer's Detrol LA, and are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product.
› Verified 1 days ago
| Provider Name | Samantha Faith Rojas |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1336472539 PECOS PAC ID: 0345551990 Enrollment ID: I20150623001908 |
News Archive
Connected health infrastructure is emerging as a binding agent for diverse devices and workflows, aiding diagnosis, monitoring and prevention in the healthcare industry. For such an infrastructure to be efficient, stakeholders must first ensure that interoperability and connectivity standards are in place.
RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that the first participant in its Phase 1/2 clinical trial of RCT-01, being tested for the treatment of chronic unilateral Achilles tendinosis, has been enrolled and their tissue biopsy sent for processing prior to intra-tendon ultrasound-guided injections.
Jiangbo Pharmaceuticals, Inc., a pharmaceutical company with its principal operations in the People's Republic of China, today announced that it has reached a settlement with the holder of its November 2007 Debenture and with the holders of its May 2008 Notes under which the Company has agreed to issue to such holders a total of 886,277 shares of its common stock as a payment for all delinquent interest and associated penalties with respect to its November 2007 Debenture and May 2008 Notes.
Amid the coronavirus disease (COVID-19) outbreak, scientists from around the globe race to fight the deadly virus. Now, a team of Harvard scientists has joined forces with Chinese experts to develop new therapies and prevent the further spread of the virus.
Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Tolterodine Tartrate Extended-release Capsules, 2 mg and 4 mg. Tolterodine Tartrate ER Capsules are the generic version of Pfizer's Detrol LA, and are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product.
› Verified 1 days ago
| Provider Name | Adriana Bentum-tilus |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1801330519 PECOS PAC ID: 7012291198 Enrollment ID: I20170309001645 |
News Archive
Connected health infrastructure is emerging as a binding agent for diverse devices and workflows, aiding diagnosis, monitoring and prevention in the healthcare industry. For such an infrastructure to be efficient, stakeholders must first ensure that interoperability and connectivity standards are in place.
RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that the first participant in its Phase 1/2 clinical trial of RCT-01, being tested for the treatment of chronic unilateral Achilles tendinosis, has been enrolled and their tissue biopsy sent for processing prior to intra-tendon ultrasound-guided injections.
Jiangbo Pharmaceuticals, Inc., a pharmaceutical company with its principal operations in the People's Republic of China, today announced that it has reached a settlement with the holder of its November 2007 Debenture and with the holders of its May 2008 Notes under which the Company has agreed to issue to such holders a total of 886,277 shares of its common stock as a payment for all delinquent interest and associated penalties with respect to its November 2007 Debenture and May 2008 Notes.
Amid the coronavirus disease (COVID-19) outbreak, scientists from around the globe race to fight the deadly virus. Now, a team of Harvard scientists has joined forces with Chinese experts to develop new therapies and prevent the further spread of the virus.
Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Tolterodine Tartrate Extended-release Capsules, 2 mg and 4 mg. Tolterodine Tartrate ER Capsules are the generic version of Pfizer's Detrol LA, and are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product.
› Verified 1 days ago
| Provider Name | Moses Enakiruvie Ekakitie |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1538831110 PECOS PAC ID: 7214329929 Enrollment ID: I20220110000025 |
News Archive
Connected health infrastructure is emerging as a binding agent for diverse devices and workflows, aiding diagnosis, monitoring and prevention in the healthcare industry. For such an infrastructure to be efficient, stakeholders must first ensure that interoperability and connectivity standards are in place.
RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that the first participant in its Phase 1/2 clinical trial of RCT-01, being tested for the treatment of chronic unilateral Achilles tendinosis, has been enrolled and their tissue biopsy sent for processing prior to intra-tendon ultrasound-guided injections.
Jiangbo Pharmaceuticals, Inc., a pharmaceutical company with its principal operations in the People's Republic of China, today announced that it has reached a settlement with the holder of its November 2007 Debenture and with the holders of its May 2008 Notes under which the Company has agreed to issue to such holders a total of 886,277 shares of its common stock as a payment for all delinquent interest and associated penalties with respect to its November 2007 Debenture and May 2008 Notes.
Amid the coronavirus disease (COVID-19) outbreak, scientists from around the globe race to fight the deadly virus. Now, a team of Harvard scientists has joined forces with Chinese experts to develop new therapies and prevent the further spread of the virus.
Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Tolterodine Tartrate Extended-release Capsules, 2 mg and 4 mg. Tolterodine Tartrate ER Capsules are the generic version of Pfizer's Detrol LA, and are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product.
› Verified 1 days ago
| Provider Name | Natascha Katovich |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1699421560 PECOS PAC ID: 0648667758 Enrollment ID: I20220420000053 |
News Archive
Connected health infrastructure is emerging as a binding agent for diverse devices and workflows, aiding diagnosis, monitoring and prevention in the healthcare industry. For such an infrastructure to be efficient, stakeholders must first ensure that interoperability and connectivity standards are in place.
RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that the first participant in its Phase 1/2 clinical trial of RCT-01, being tested for the treatment of chronic unilateral Achilles tendinosis, has been enrolled and their tissue biopsy sent for processing prior to intra-tendon ultrasound-guided injections.
Jiangbo Pharmaceuticals, Inc., a pharmaceutical company with its principal operations in the People's Republic of China, today announced that it has reached a settlement with the holder of its November 2007 Debenture and with the holders of its May 2008 Notes under which the Company has agreed to issue to such holders a total of 886,277 shares of its common stock as a payment for all delinquent interest and associated penalties with respect to its November 2007 Debenture and May 2008 Notes.
Amid the coronavirus disease (COVID-19) outbreak, scientists from around the globe race to fight the deadly virus. Now, a team of Harvard scientists has joined forces with Chinese experts to develop new therapies and prevent the further spread of the virus.
Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Tolterodine Tartrate Extended-release Capsules, 2 mg and 4 mg. Tolterodine Tartrate ER Capsules are the generic version of Pfizer's Detrol LA, and are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product.
› Verified 1 days ago
| Provider Name | Timothy Mahaney |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1386329514 PECOS PAC ID: 8224498613 Enrollment ID: I20230717003156 |
News Archive
Connected health infrastructure is emerging as a binding agent for diverse devices and workflows, aiding diagnosis, monitoring and prevention in the healthcare industry. For such an infrastructure to be efficient, stakeholders must first ensure that interoperability and connectivity standards are in place.
RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that the first participant in its Phase 1/2 clinical trial of RCT-01, being tested for the treatment of chronic unilateral Achilles tendinosis, has been enrolled and their tissue biopsy sent for processing prior to intra-tendon ultrasound-guided injections.
Jiangbo Pharmaceuticals, Inc., a pharmaceutical company with its principal operations in the People's Republic of China, today announced that it has reached a settlement with the holder of its November 2007 Debenture and with the holders of its May 2008 Notes under which the Company has agreed to issue to such holders a total of 886,277 shares of its common stock as a payment for all delinquent interest and associated penalties with respect to its November 2007 Debenture and May 2008 Notes.
Amid the coronavirus disease (COVID-19) outbreak, scientists from around the globe race to fight the deadly virus. Now, a team of Harvard scientists has joined forces with Chinese experts to develop new therapies and prevent the further spread of the virus.
Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Tolterodine Tartrate Extended-release Capsules, 2 mg and 4 mg. Tolterodine Tartrate ER Capsules are the generic version of Pfizer's Detrol LA, and are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product.
› Verified 1 days ago
| Provider Name | Debbie Raymond |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1336780857 PECOS PAC ID: 1951755644 Enrollment ID: I20230928003555 |
News Archive
Connected health infrastructure is emerging as a binding agent for diverse devices and workflows, aiding diagnosis, monitoring and prevention in the healthcare industry. For such an infrastructure to be efficient, stakeholders must first ensure that interoperability and connectivity standards are in place.
RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that the first participant in its Phase 1/2 clinical trial of RCT-01, being tested for the treatment of chronic unilateral Achilles tendinosis, has been enrolled and their tissue biopsy sent for processing prior to intra-tendon ultrasound-guided injections.
Jiangbo Pharmaceuticals, Inc., a pharmaceutical company with its principal operations in the People's Republic of China, today announced that it has reached a settlement with the holder of its November 2007 Debenture and with the holders of its May 2008 Notes under which the Company has agreed to issue to such holders a total of 886,277 shares of its common stock as a payment for all delinquent interest and associated penalties with respect to its November 2007 Debenture and May 2008 Notes.
Amid the coronavirus disease (COVID-19) outbreak, scientists from around the globe race to fight the deadly virus. Now, a team of Harvard scientists has joined forces with Chinese experts to develop new therapies and prevent the further spread of the virus.
Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Tolterodine Tartrate Extended-release Capsules, 2 mg and 4 mg. Tolterodine Tartrate ER Capsules are the generic version of Pfizer's Detrol LA, and are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product.
› Verified 1 days ago
| Provider Name | Marie Emmanuel |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1457123176 PECOS PAC ID: 8426408535 Enrollment ID: I20240102000437 |
News Archive
Connected health infrastructure is emerging as a binding agent for diverse devices and workflows, aiding diagnosis, monitoring and prevention in the healthcare industry. For such an infrastructure to be efficient, stakeholders must first ensure that interoperability and connectivity standards are in place.
RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that the first participant in its Phase 1/2 clinical trial of RCT-01, being tested for the treatment of chronic unilateral Achilles tendinosis, has been enrolled and their tissue biopsy sent for processing prior to intra-tendon ultrasound-guided injections.
Jiangbo Pharmaceuticals, Inc., a pharmaceutical company with its principal operations in the People's Republic of China, today announced that it has reached a settlement with the holder of its November 2007 Debenture and with the holders of its May 2008 Notes under which the Company has agreed to issue to such holders a total of 886,277 shares of its common stock as a payment for all delinquent interest and associated penalties with respect to its November 2007 Debenture and May 2008 Notes.
Amid the coronavirus disease (COVID-19) outbreak, scientists from around the globe race to fight the deadly virus. Now, a team of Harvard scientists has joined forces with Chinese experts to develop new therapies and prevent the further spread of the virus.
Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Tolterodine Tartrate Extended-release Capsules, 2 mg and 4 mg. Tolterodine Tartrate ER Capsules are the generic version of Pfizer's Detrol LA, and are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product.
› Verified 1 days ago
News Archive
Connected health infrastructure is emerging as a binding agent for diverse devices and workflows, aiding diagnosis, monitoring and prevention in the healthcare industry. For such an infrastructure to be efficient, stakeholders must first ensure that interoperability and connectivity standards are in place.
RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that the first participant in its Phase 1/2 clinical trial of RCT-01, being tested for the treatment of chronic unilateral Achilles tendinosis, has been enrolled and their tissue biopsy sent for processing prior to intra-tendon ultrasound-guided injections.
Jiangbo Pharmaceuticals, Inc., a pharmaceutical company with its principal operations in the People's Republic of China, today announced that it has reached a settlement with the holder of its November 2007 Debenture and with the holders of its May 2008 Notes under which the Company has agreed to issue to such holders a total of 886,277 shares of its common stock as a payment for all delinquent interest and associated penalties with respect to its November 2007 Debenture and May 2008 Notes.
Amid the coronavirus disease (COVID-19) outbreak, scientists from around the globe race to fight the deadly virus. Now, a team of Harvard scientists has joined forces with Chinese experts to develop new therapies and prevent the further spread of the virus.
Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Tolterodine Tartrate Extended-release Capsules, 2 mg and 4 mg. Tolterodine Tartrate ER Capsules are the generic version of Pfizer's Detrol LA, and are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product.
› Verified 1 days ago
Tranquility Therapy Services, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 260 S Marion Ave Ste 135, Lake City, FL 32025 Phone: 386-965-6901 Fax: 386-406-8348 | |
Southern Interventional Pain Center Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 619 Sw Baya Dr Ste 102, Lake City, FL 32025 Phone: 386-361-3400 Fax: 855-313-1262 | |
Resolutions Heatlh Alliance Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 492 W Duval St, Lake City, FL 32055 Phone: 386-754-9005 Fax: 386-754-9011 | |
Behavioral Health Associates Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 343 E Duval St, Suite 101, Lake City, FL 32055 Phone: 386-752-7116 Fax: 386-752-7188 | |
Sacred Wings Counseling, Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 826 Sw Main Blvd Ste 102, Lake City, FL 32025 Phone: 386-984-5366 Fax: 386-287-6525 | |
Tranquility Therapy Services, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 260 S Marion Ave Ste 135, Lake City, FL 32025 Phone: 386-965-6901 Fax: 386-406-8348 | |
Meridian Behavioral Healthcare Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 173 Se Baya Dr, Lake City, FL 32025 Phone: 386-755-0337 |